Conatus Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Conatus Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Conatus Pharmaceuticals: 16 sponsored US clinical trials, none currently recruiting.
Conatus Pharmaceuticals sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 0 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hepatic Cirrhosis, with 1 trials.
Top-decile sponsor footprint
Conatus Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
16 total, page 1 of 1
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
NCT03479125
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
NCT02686762
A Study of IDN-6556 in Subjects With Liver Cirrhosis
NCT02230670
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
NCT02230683
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
NCT02138253
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
NCT02121860
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
NCT02077374
PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
NCT02039817
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
NCT01937130
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
NCT01912404
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
NCT01273064
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
NCT01051921
CTS-1027 in Interferon-Naive Hepatitis C Patients
NCT00925990
Study of CTS-1027 in Hepatitis C Patients
NCT00570336
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
NCT00088140
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
NCT00080236
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 13 |
Therapeutic Areas
How the Conatus Pharmaceuticals early-phase archive is shaped
16 indexed studies, none listed as recruiting (0% open); 12 completed (75%).
Phase mix: 0 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Hepatic Cirrhosis (1 trial), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Conatus Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Conatus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 archived trials
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Conatus Pharmaceuticals page
16 registered trials is a research-attention snapshot, not an endorsement of Conatus Pharmaceuticals or any single study.
- None of Conatus Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hepatic Cirrhosis is the condition Conatus Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hepatic Cirrhosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Conatus Pharmaceuticals pipeline card: 16 registered trials from official public datasets.Report a data error.